Cystic Fibrosis - a very common genetic disease among the population - a general review
DOI:
https://doi.org/10.12775/JEHS.2023.40.01.004Keywords
cystic fibrosis, cf, cftr, cf diagnosis, cftr geneAbstract
Cystic fibrosis is the most common genetic disease inherited in an autosomal recessive manner occurring among populations of Caucasian descent. It is an incurable, multi-composition monogenic disease caused by mutations in the gene encoding the CFTR protein, which is a membrane conduction regulator. Mutations of the CFTR gene can cause symptoms from many organs and systems as a result of extracellular secretion disorders, but the main symptoms of this disease are related to the respiratory system and digestive system. Although a lot of changes have occurred in regards to treating the disease and making the lives of sick patients easier and longer, there is still a long way to go. New therapy methods bring a lot hope and get us closer to reaching the ultimate goal of successfully treating all patients with CF. In this review, we summarize the information available about CF for the present moment, diagnostic methods, current methods of treatment and discuss possible future outcomes of therapy.
References
Scotet V, L'Hostis C, Férec C. The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes (Basel). 2020 May 26;11(6):589. doi: 10.3390/genes11060589. PMID: 32466381; PMCID: PMC7348877.
Chen Q, Shen Y, Zheng J. A review of cystic fibrosis: Basic and clinical aspects. Animal Model Exp Med. 2021 Sep 16;4(3):220-232. doi: 10.1002/ame2.12180. PMID: 34557648; PMCID: PMC8446696.
Bear CE. A Therapy for Most with Cystic Fibrosis. Cell. 2020 Jan 23;180(2):211. doi: 10.1016/j.cell.2019.12.032. PMID: 31978337.
The Clinical and Functional Translation of CFTR (CFTR2); available at http://cftr2.org.
Pierre-Régis Burgel, Espérie Burnet, Lucile Regard, Clémence Martin,The Changing Epidemiology of Cystic Fibrosis: The Implications for Adult Care, Chest, Volume 163, Issue 1, 2023, Pages 89-99, ISSN 0012-3692, https://doi.org/10.1016/j.chest.2022.07.004.
Jonathan Guo, Anna Garratt, Andrew Hill, Worldwide rates of diagnosis and effective treatment for cystic fibrosis, Journal of Cystic Fibrosis, Volume 21, Issue 3, 2022, Pages 456-462, ISSN 1569-1993, https://doi.org/10.1016/j.jcf.2022.01.009.
Castellani C, Picci L, Tridello G, et al.; Veneto CF Lab Network. Cystic fibrosis carrier screening effects on birth prevalence and newborn screening. Genet Med. 2016;18(2):145-151. doi:10.1038/gim.2015.68
Cystic Fibrosis Foundation; Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, Michel SH, Parad RB, White TB, Farrell PM, Marshall BC, Accurso FJ. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr. 2009 Dec;155(6 Suppl):S73-93. doi: 10.1016/j.jpeds.2009.09.001. PMID: 19914445; PMCID: PMC6324931.
Diagnosis of Cystic Fibrosis in Screened Populations, Farrell, Philip M. et al., The Journal of Pediatrics, Volume 181, S33 - S44.e2, https://doi.org/10.1016/j.jpeds.2016.09.065
Guimbellot J, Sharma J, Rowe SM. Toward inclusive therapy with CFTR modulators: Progress and challenges. Pediatr Pulmonol. 2017 Nov;52(S48):S4-S14. doi: 10.1002/ppul.23773. Epub 2017 Sep 7. PMID: 28881097; PMCID: PMC6208153.
Gokdemir Y, Karadag BT. Sweat Testing and Recent Advances. Front Pediatr. 2021 May 4;9:649904. doi: 10.3389/fped.2021.649904. PMID: 34017807; PMCID: PMC8129525.
Nutrition in Children and Adults Clinical Care Guidelines. Cystic Fibrosis Foundation, accessed on 28.04.23.
Freswick PN, Reid EK, Mascarenhas MR. Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis. Nutrients. 2022 Mar 23;14(7):1341. doi: 10.3390/nu14071341. PMID: 35405954; PMCID: PMC9003370.
Farmakoterapia mukowiscydozy, Dorota Sands, Justyna Milczewska, Monika Mielus, Klinika Pediatrii, Instytut Matki i Dziecka, Warszawa, Pediatr Dypl. 2012;16(2):64-73.
Fizjoterapia chorych na mukowiscydozę: Wydanie I, Teresa Orlik
Mielus M., Walicka-Serzysko K., Sands D.: Rozpoznawanie i leczenie mukowiscydozy. Podsumowanie wytycznych European Cystic Fibrosis Society 2018. Med. Prakt., 2019; 6
Sands D, Walicka-Serzysko K, Doniec Z, Mastalerz-Migas A, Batura-Gabryel H, Pierzchała W. ReCOMmendations for management of cystic fibrosis for general PrActitionerS – COMPAS CF. Lekarz POZ. 2017;3(5):299-322.
Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2018 Sep 6;9(9):CD001127. doi: 10.1002/14651858.CD001127.pub4. Update in: Cochrane Database Syst Rev. 2021 Mar 18;3:CD001127. PMID: 30187450; PMCID: PMC6513278.
Aspinall SA, Mackintosh KA, Hill DM, Cope B, McNarry MA. Evaluating the Effect of Kaftrio on Perspectives of Health and Wellbeing in Individuals with Cystic Fibrosis. Int J Environ Res Public Health. 2022 May 17;19(10):6114. doi: 10.3390/ijerph19106114. PMID: 35627651; PMCID: PMC9141876.
Andrea Lopez, Conor Daly, Gabriela Vega-Hernandez, Gordon MacGregor, Jaime L. Rubin, Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del, Journal of Cystic Fibrosis, 2023, ISSN 1569-1993, https://doi.org/10.1016/j.jcf.2023.02.004.
Cystic fibrosis: frequency. MedlinePlus. Accessed on 28.04.23.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Julia Rutkowska, Klaudia Skorek, Rafał Babiak, Karolina Bajak, Paulina Czuchryta, Anastazja Domańska, Agnieszka Gawęda, Agata Grabek, Żaneta Rzęsa-Tokarczyk, Agnieszka Urbańczyk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 789
Number of citations: 0
